- Tytuł:
- Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
- Autorzy:
- Źródło:
- Breast Cancer Research and Treatment. January 2015 149(1):171-179
Czasopismo naukowe